Nektar Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Nektar Therapeutics
NKTR Stock  USD 43.84  0.42  0.97%   
Nektar Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Nektar Therapeutics' valuation are provided below:
Gross Profit
54.6 M
Profit Margin
(1.93)
Market Capitalization
883.2 M
Enterprise Value Revenue
11.261
Revenue
62.6 M
There are over one hundred nineteen available fundamental ratios for Nektar Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check Nektar Therapeutics' last-minute fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/05/2026, Market Cap is likely to drop to about 163.5 M. In addition to that, Enterprise Value is likely to drop to about 213.4 M

Nektar Therapeutics Total Revenue

160.52 Million

Check Nektar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nektar Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 M, Interest Expense of 24.1 M or Total Revenue of 160.5 M, as well as many indicators such as Price To Sales Ratio of 2.12, Dividend Yield of 0.0 or PTB Ratio of 2.69. Nektar financial statements analysis is a perfect complement when working with Nektar Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Nektar Stock
Check out the analysis of Nektar Therapeutics Correlation against competitors.
To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.

Nektar Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets695.3 M349.4 M754 M
Pretty Stable
Short and Long Term Debt Total229.7 M117.9 M188.4 M
Very volatile
Other Current Liabilities30.9 M34.5 M31.5 M
Slightly volatile
Total Current Liabilities87.4 M70.6 M99 M
Very volatile
Property Plant And Equipment Net12.9 M13.6 M73.4 M
Very volatile
Accounts Payable8.4 M13.3 M8.3 M
Slightly volatile
Cash70.8 M50.9 M60.4 M
Slightly volatile
Non Current Assets Total46.5 M48.9 M216.6 M
Very volatile
Non Currrent Assets Other8.1 M4.2 M6.7 M
Slightly volatile
Cash And Short Term Investments432.8 M293.5 M484.9 M
Slightly volatile
Common Stock Shares Outstanding26.3 M15.8 M42.3 M
Pretty Stable
Liabilities And Stockholders Equity695.3 M349.4 M754 M
Pretty Stable
Non Current Liabilities Total298.4 M209 M289.9 M
Very volatile
Other Current Assets4.9 M5.1 M17.5 M
Slightly volatile
Other Stockholder Equity4.4 B4.2 B2.7 B
Slightly volatile
Total Liabilities385.8 M279.6 M388.9 M
Very volatile
Property Plant And Equipment Gross30.3 M31.9 M81.5 M
Pretty Stable
Total Current Assets470.3 M300.5 M526.9 M
Pretty Stable
Short Term Debt34.8 M22.8 M48.8 M
Pretty Stable
Common Stock Total Equity16.2 K17.1 K8 M
Slightly volatile
Short Term Investments400.8 M242.6 M431.8 M
Pretty Stable
Common Stock16.2 K17.1 K8 M
Slightly volatile
Net Receivables1.8 M1.9 M12.7 M
Very volatile
Other Liabilities105.7 M187.4 M138.9 M
Slightly volatile
Other Assets2.5 M2.6 M22.3 M
Very volatile
Long Term Debt200.4 M222.3 M211.2 M
Slightly volatile
Property Plant Equipment77.9 M77.3 M79.2 M
Pretty Stable
Intangible Assets23 M24.2 M54.4 M
Slightly volatile
Long Term Debt Total191.7 M284 M198 M
Slightly volatile
Capital Surpluse2.6 B4 B2.6 B
Slightly volatile
Capital Lease Obligations77.2 M117.9 M80.1 M
Slightly volatile
Deferred Long Term Liabilities16.3 M17.1 M45.9 M
Slightly volatile
Non Current Liabilities Other147.7 M113.9 M126.4 M
Pretty Stable
Short and Long Term Debt246.1 M286 M216.3 M
Slightly volatile
Net Invested Capital51.9 M54.7 M512 M
Very volatile
Net Working Capital170.9 M179.9 M448.8 M
Very volatile
Capital Stock20.1 K21.9 K18 K
Slightly volatile

Nektar Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.8 M5 M10.4 M
Slightly volatile
Total Revenue160.5 M113.2 M195.6 M
Very volatile
Gross Profit131.1 M77.9 M168.7 M
Very volatile
Other Operating Expenses256.9 M234.2 M305.6 M
Slightly volatile
Total Operating Expenses227.5 M198.9 M278.7 M
Slightly volatile
Research Development182.9 M139 M217.4 M
Pretty Stable
Selling General Administrative53.6 M88.3 M65.3 M
Slightly volatile
Non Recurring13.6 M18.4 M13.5 M
Slightly volatile
Interest Income15 M13.1 M23.6 M
Slightly volatile
Reconciled Depreciation3.8 M4 M12 M
Slightly volatile
Selling And Marketing Expenses1.8 M2 M2.2 M
Slightly volatile

Nektar Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow66.7 M40.6 M57.5 M
Slightly volatile
Depreciation4.8 M5 M11 M
Slightly volatile
Capital Expenditures1.3 M1.3 M8 M
Pretty Stable
End Period Cash Flow70.8 M50.9 M60.4 M
Slightly volatile
Stock Based Compensation30.8 M24.9 M41 M
Slightly volatile
Change To Netincome50.1 M58.3 M45.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.122.2312.7036
Slightly volatile
Days Sales Outstanding5.15.3730.2116
Very volatile
Stock Based Compensation To Revenue0.170.20.301
Slightly volatile
Capex To Depreciation0.370.380.8054
Slightly volatile
EV To Sales2.772.9213.2633
Slightly volatile
Inventory Turnover3.212.622.1487
Pretty Stable
Days Of Inventory On Hand141144190
Very volatile
Sales General And Administrative To Revenue0.350.70.5505
Slightly volatile
Research And Ddevelopement To Revenue1.261.111.7131
Very volatile
Capex To Revenue0.01630.01720.1083
Slightly volatile
Cash Per Share20.3421.4143.7638
Very volatile
Income Quality1.41.330.9852
Pretty Stable
Intangibles To Total Assets0.150.120.1225
Slightly volatile
Current Ratio7.234.896.57
Pretty Stable
Receivables Turnover57.8155.0630.7158
Pretty Stable
Capex Per Share0.120.10710.8893
Slightly volatile
Revenue Per Share6.146.4617.8453
Pretty Stable
Interest Debt Per Share10.4110.9619.9156
Slightly volatile
Debt To Assets0.260.30.273
Very volatile
Graham Number342385420
Slightly volatile
Operating Cycle5.15.37177
Pretty Stable
Ebt Per Ebit0.991.021.4429
Pretty Stable
Long Term Debt To Capitalization0.110.12570.5509
Slightly volatile
Total Debt To Capitalization0.430.570.6269
Slightly volatile
Quick Ratio7.114.896.4315
Pretty Stable
Net Income Per E B T0.740.90.9835
Slightly volatile
Cash Ratio1.460.831.1732
Pretty Stable
Days Of Inventory Outstanding141144190
Very volatile
Days Of Sales Outstanding5.15.3730.2116
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.281.161.0949
Pretty Stable
Fixed Asset Turnover7.877.494.3345
Pretty Stable
Debt Ratio0.260.30.273
Very volatile
Price Sales Ratio2.122.2312.7036
Slightly volatile
Asset Turnover0.180.290.2639
Very volatile
Gross Profit Margin0.890.790.8195
Slightly volatile

Nektar Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap163.5 M172.1 M2 B
Pretty Stable
Enterprise Value213.4 M224.6 M2.1 B
Pretty Stable

Nektar Fundamental Market Drivers

Nektar Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Nektar Therapeutics Financial Statements

Nektar Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Nektar Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Nektar Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Nektar Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-7.4 M-7 M
Total Revenue113.2 M160.5 M
Cost Of Revenue27.6 M26.7 M
Stock Based Compensation To Revenue 0.20  0.17 
Sales General And Administrative To Revenue 0.70  0.35 
Research And Ddevelopement To Revenue 1.11  1.26 
Capex To Revenue 0.02  0.02 
Revenue Per Share 6.46  6.14 
Ebit Per Revenue(1.23)(1.29)

Pair Trading with Nektar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Nektar Stock

  0.78VTRS ViatrisPairCorr
  0.78TLRY Tilray Inc Earnings Call This WeekPairCorr
  0.72BMY Bristol Myers SquibbPairCorr
  0.71NVS Novartis AG ADRPairCorr
  0.57MRK Merck CompanyPairCorr
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Nektar Stock Analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY